December 2023
65th American Society of Hematology (ASH) Annual Meeting
June 2023
Clinical Immunology Society (CIS) Annual Meeting / European Hematology Association (EHA) Annual Congress
May 2023
Clinical Immunology Society (CIS) Annual Meeting
December 2022
64th American Society of Hematology (ASH) Annual Meeting
- Mavorixafor for Patients With Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study
- Prevalence of Chronic Neutropenic Disorders in the United States: A Retrospective Analysis of a Large Claims Database
- Patient and Health Care Professional Perspectives on Quality of Life and Unmet Needs of People With Chronic Neutropenia: A Survey-Based Assessment
- The Morphological Spectrum of Myelokathexis in WHIM Syndrome and Germline CXCR4 Variants: New Insights Into Cellular Changes in the Bone Marrow and Peripheral Blood
October 2022
National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit
October 2022
The European Society for Immunodeficiencies (ESID)
September 2022
North American Immuno-Hematology Clinical Education & Research (NICER) Symposium
June 2022
European Hematology Association (EHA) Annual Congress
April 2022
American Association for Cancer Research (AACR) Annual Meeting
April 2022
Clinical Immunology Society (CIS) Annual Meeting
- PATH4WARD: A Genetic Testing Program to Aid in Molecular Diagnosis of Congenital Neutropenia and Other Primary Immunodeficiencies Including WHIM Syndrome
- 4WHIM: Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients With WHIM Syndrome via a Global, Phase 3, Randomized, Placebo-Controlled Trial With Open-Label Extension
February 2022
American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
December 2021
63rd American Society of Hematology (ASH) Annual Meeting
- Comprehensive in Vitro Characterization of CXCR4-WHIM variants to Decipher Genotype–Phenotype Correlations in WHIM Syndrome
- Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States
- Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström’s Macroglobulinemia with MYD88 and CXCR4 Mutations
- Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients With WHIM Syndrome: Results From the Long-Term Extension of theOpen-Label Phase 2 Study
October 2021
National Organization for Rare Disorders (NORD) Rare Disease and Orphan Products Breakthrough Summit
June 2021
26ᵗʰ European Hematology Association (EHA) Annual Congress
June 2020
25ᵗʰ European Hematology Association (EHA) Annual Congress
September 2019
European Society for Medical Oncology (ESMO) 2019 Congress
December 2018
60th Annual Meeting of the American Society of Hematology
November 2018
The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
October 2018
European Society for Medical Oncology (ESMO) 2018 Congress
October 2018
National Organization for Rare Disorders (NORD) Rare Disease and Orphan Products Breakthrough Summit
- Review of Case Report Literature Highlights that WHIM Syndrome has Serious Long-term Outcomes Beyond Warts and Infections
- First WHIM Genetic Screening Study Developed Through a Collaborative Effort Among Academia, Patient Foundation, and Sponsors
- Emerging Picture of Morbidity in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
June 2018
23rd Congress of the European Hematology Association (EHA)
June 2018
2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 2018
16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
April 2018
2018 American Association for Cancer Research (AACR) Annual Meeting
December 2017
59th Annual Meeting of the American Society for Hematology (ASH)
November 2017
Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 2017
2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
September 2017
European Society of Medical Oncology 2017 Congress
November 2016
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
April 2016